Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Efficacy and outcomes of [<sup>177</sup>Lu]Lu-PSMA-617 in patients with mCRPC treated with or without concurrent ARPI: a real-world single-center analysis.

European journal of nuclear medicine and molecular imaging·2026

Same author

Frequency and new-onset rates of nausea and fatigue in ¹⁷⁷Lu-PSMA therapy with standardized premedication.

Nuklearmedizin. Nuclear medicine·2026

Same author

Parathyroid Carcinoma Mimicking a Parathyroid Adenoma on [ 18 F]F-Choline-PET With Occult Metastases.

Clinical nuclear medicine·2026

Same author

Outcome-driven dosimetry optimization for [<sup>177</sup>Lu]Lu-PSMA-617 radiopharmaceutical therapy: proof of concept on single time point dosimetry optimization.

European journal of nuclear medicine and molecular imaging·2026

Same author

Impact of scan duration and scatter correction on quantitative accuracy in Yttrium-90 PET/CT imaging using LAFOV and SAFOV systems: a phantom and clinical evaluation.

EJNMMI physics·2026

Same author

Development and validation of prostate-specific membrane antigen-adjusted Prostate Imaging Reporting and Data System: A new approach to enhancing the accuracy of diagnosing treatment-naïve primary prostate cancer.

Asian journal of urology·2026

Search research articles

Related Experiment Video

Updated: Nov 4, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Prostate Cancer Theranostics: PSMA Targeted Therapy.

Robert Seifert¹, Ian L Alberts², Ali Afshar-Oromieh²

¹Department of Nuclear Medicine, University Hospital Münster, Münster, Germany; Department of Nuclear Medicine, University Hospital Essen, Essen, Germany; West German Cancer Center (WTZ); German Cancer Consortium (DKTK).

|May 31, 2021

Summary

Prostate-specific membrane antigen (PSMA) targeted therapies, particularly Lu-PSMA, are revolutionizing prostate cancer care. This review highlights PSMA

Keywords:

PSMA Prostate cancer Prostate-specific membrane antigen Theranostics

More Related Videos

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

Related Experiment Videos

Last Updated: Nov 4, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

Area of Science:

Oncology
Nuclear Medicine
Radiopharmaceutical Therapy

Background:

Prostate-specific membrane antigen (PSMA) is a key target in prostate cancer research.
PSMA-targeted agents have advanced imaging and therapy for prostate cancer.
Lutetium-177-conjugated PSMA (Lu-PSMA) shows significant promise in clinical trials.

Purpose of the Study:

To review the historical development of PSMA-targeted therapy.
To outline current applications and future directions in PSMA therapy.
To emphasize the role of PSMA PET imaging in guiding radioligand therapy.

Main Methods:

Literature review of PSMA-targeted imaging and therapy studies.
Analysis of clinical trial data for Lu-PSMA efficacy.
Focus on PSMA PET-guided treatment strategies.

Main Results:

PSMA-targeted approaches have transformed prostate cancer management, especially for metastatic castration-resistant disease.
Lu-PSMA has demonstrated favorable outcomes in various clinical settings.
PSMA PET imaging is crucial for patient selection and treatment monitoring.

Conclusions:

PSMA-targeted therapy represents a major advancement in prostate cancer treatment.
Future developments will likely focus on refining PSMA-based radioligand therapies and imaging.
Integrating PSMA PET with Lu-PSMA therapy offers a personalized approach to patient care.